Codon AG (CHIX:CNWKD) Current Accrued Expense : €0.00 Mil (As of Jun. 2022)

View and export this data going back to 2015. Start your Free Trial

What is Codon AG Current Accrued Expense?

Codon AG's Current Accrued Expense for the quarter that ended in Jun. 2022 was €0.00 Mil.

Codon AG Current Accrued Expense Historical Data

The historical data trend for Codon AG's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Codon AG Current Accrued Expense Chart

Codon AG Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Current Accrued Expense

Get a 7-Day Free Trial

Codon AG Semi-Annual Data
	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Current Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Codon AG Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Codon AG Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Codon AG's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Codon AG (CHIX:CNWKD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codon AG (CHIX:CNWKd) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Warthestrasse 21, Teltow, DEU, 14513

Website

http://www.codon.de

Codon AG develops, produces and distributes autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint that uses only the patient's own cartilage cells (autologous chondrocytes). CODON's method is currently used in over 200 clinics in Germany and more than 14,000 patients have already been treated.

Codon AG (CHIX:CNWKD) Headlines

No Headlines